Esmolol

Esmolol, sold under the brand name Brevibloc, is a cardio selective beta₁ receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages.

It is a class II antiarrhythmic. Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.

It was patented in 1980 and approved for medical use in 1987.

To terminate supraventricular tachycardia,

Episodic atrial fibrillation or flutter,

Arrhythmia during anaesthesia,

To reduce HR and BP during and after cardiac surgery, and

In early treatment of myocardial infarction.